These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


374 related items for PubMed ID: 15284362

  • 1. Vascular calcification in patients with end-stage renal disease.
    Floege J, Ketteler M.
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V59-66. PubMed ID: 15284362
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular calcification in patients with end-stage renal disease.
    Pecovnik-Balon B.
    Ther Apher Dial; 2005 Jun; 9(3):208-10. PubMed ID: 15966990
    [Abstract] [Full Text] [Related]

  • 3. Pathophysiology of vascular calcification in chronic kidney disease.
    Moe SM, Chen NX.
    Circ Res; 2004 Sep 17; 95(6):560-7. PubMed ID: 15375022
    [Abstract] [Full Text] [Related]

  • 4. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
    Burke SK, Dillon MA, Hemken DE, Rezabek MS, Balwit JM.
    Adv Ren Replace Ther; 2003 Apr 17; 10(2):133-45. PubMed ID: 12879374
    [Abstract] [Full Text] [Related]

  • 5. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.
    Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M.
    Nephrol Dial Transplant; 2010 Aug 17; 25(8):2672-9. PubMed ID: 20172849
    [Abstract] [Full Text] [Related]

  • 6. Determinants of progressive vascular calcification in haemodialysis patients.
    Chertow GM, Raggi P, Chasan-Taber S, Bommer J, Holzer H, Burke SK.
    Nephrol Dial Transplant; 2004 Jun 17; 19(6):1489-96. PubMed ID: 15102961
    [Abstract] [Full Text] [Related]

  • 7. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD.
    Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM.
    J Am Soc Nephrol; 2004 Nov 17; 15(11):2857-67. PubMed ID: 15504939
    [Abstract] [Full Text] [Related]

  • 8. [Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes].
    Martola L, Elinder CG, Stenvinkel P.
    Lakartidningen; 2003 Dec 11; 100(50):4180-3. PubMed ID: 14717005
    [Abstract] [Full Text] [Related]

  • 9. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis.
    Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM.
    Circulation; 2008 Oct 21; 118(17):1748-57. PubMed ID: 18838561
    [Abstract] [Full Text] [Related]

  • 10. Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients.
    Yamada K, Fujimoto S, Tokura T, Fukudome K, Ochiai H, Komatsu H, Sato Y, Hara S, Eto T.
    Ren Fail; 2005 Oct 21; 27(4):361-5. PubMed ID: 16060120
    [Abstract] [Full Text] [Related]

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov 21; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 12. Length of interdialytic interval influences serum calcium and phosphorus concentrations.
    Sigrist MK, Devlin L, Taal MW, Fluck RJ, McIntyre CW.
    Nephrol Dial Transplant; 2005 Aug 21; 20(8):1643-6. PubMed ID: 15870223
    [Abstract] [Full Text] [Related]

  • 13. IL-18 is involved in vascular injury in end-stage renal disease patients.
    Porazko T, Kúzniar J, Kusztal M, Kúzniar TJ, Weyde W, Kuriata-Kordek M, Klinger M.
    Nephrol Dial Transplant; 2009 Feb 21; 24(2):589-96. PubMed ID: 18775894
    [Abstract] [Full Text] [Related]

  • 14. Different routes bridging calcium in Japanese hemodialysis patients.
    Hamano T, Fujii N, Ito T, Imai E.
    Ther Apher Dial; 2005 Feb 21; 9(1):32-8. PubMed ID: 15828903
    [Abstract] [Full Text] [Related]

  • 15. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density.
    Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J.
    Nephrol Dial Transplant; 2005 Aug 21; 20(8):1653-61. PubMed ID: 15930018
    [Abstract] [Full Text] [Related]

  • 16. Cardiac calcifications: Fetuin-A and other risk factors in hemodialysis patients.
    Coen G, Manni M, Agnoli A, Balducci A, Dessi M, De Angelis S, Jankovic L, Mantella D, Morosetti M, Naticchia A, Nofroni I, Romagnoli A, Gallucci MT, Tomassini M, Simonetti G, Splendiani G.
    ASAIO J; 2006 Aug 21; 52(2):150-6. PubMed ID: 16557100
    [Abstract] [Full Text] [Related]

  • 17. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
    Nagano N, Miyata S, Obana S, Kobayashi N, Fukushima N, Burke SK, Wada M.
    Nephrol Dial Transplant; 2003 Oct 21; 18(10):2014-23. PubMed ID: 13679475
    [Abstract] [Full Text] [Related]

  • 18. [Prevention of extraskeletal calcifications in uremia].
    Cozzolino M, Galassi A, Bellasi A, Butti A, Zoni U, Gallieni M, Brancaccio D.
    G Ital Nefrol; 2005 Oct 21; 22 Suppl 31():S53-5. PubMed ID: 15786403
    [Abstract] [Full Text] [Related]

  • 19. Slowing the progression of vascular calcification in hemodialysis.
    Chertow GM.
    J Am Soc Nephrol; 2003 Sep 21; 14(9 Suppl 4):S310-4. PubMed ID: 12939387
    [Abstract] [Full Text] [Related]

  • 20. [Front line of management of hyperphosphatemia in hemodialysis patients].
    Yumita S.
    Clin Calcium; 2004 May 21; 14(5):771-7. PubMed ID: 15577041
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 19.